PB2134 THE IMPACT OF COMORBIDITY ON OVERALL SURVIVAL IN MULTIPLE MYELOMA

Abstract

Background:The median age at diagnosis of multiple myeloma (MM) is 66 years. Comorbidity is registered in 40% cases. This can have an impact on overall survival, frequency of complications and duration of hospitalizationAims:The aim of this study was to analyze the impact of comorbidity on overall survival in patients with MM.MethodsThe study included 156 patients with newly diagnosed MM. For each patient a comorbidity score was calculated by using Charlson Comorbidity index (CCI), Cumulative Illness Rating Scale (CIRS), Freiburg Comorbidity index (FCI), Kaplan‐Feinstein index (KFI), Satariano Index (SI). The patients with CCI > 2, CIRS > 5, SI > 0, FCI > 1, KFI > 2 score were defined as high risk group, others were considered as the group of standard risk. Primary endpoint was overall survival. The survival analysis including creation of the Kaplan‐Meier survival curves was performed with use of IBM SPSS Statistics 21 The hypothesis was verificated by log‐rank test.Results:CIRS, KFI and SI did not show statistically significant difference in all groups. OS was significantly lower in high risk group estimated by CCI (96 vs 65 months, log rank p < 0.05). However, age is also included in calculating of this comorbidity index. Due to median age at diagnosis (more than 60 years) the majority of patients is classified as high risk group CCI based only on age. Karnofsky performance status, glomerular filtration rate <30 ml/min and pulmonary diseases were used for estimation by FCI. OS in high risk group was 43 months in comparison to 86 months in group of standard risk (p < 0.05). 2 patients with FCI = 3 had extremely low OS (less than 2 months).Summary/Conclusion:Comorbidity has an impact on OS in patients with MM. According to our analysis, the most valid prognostic instruments turned out to be FCI and CCI. These indices can be used to predict clinical outcomes.image